← 返回前沿论文

免疫球蛋白和血清蛋白损害恶性腹水中的抗肿瘤 NK 细胞效应功能

英文原题:Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.

查看英文原题

Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.

PubMed 2024/04/05(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的数据显示,生物体液中高浓度的蛋白质能够抑制 NK 细胞的抗肿瘤活性,这一作用独立于电解质失衡所介导的机制。腹水中的免疫球蛋白与特异性治疗性抗体之间的竞争性干扰可能会降低基于抗体的疗法的疗效,在基于抗体的免疫治疗中应予以考虑。

研究思路结论见上方概要

恶性腹水提示卵巢癌进展并预示不良临床结局。腹水中多种成分诱导肿瘤与免疫细胞之间的免疫抑制性交互作用,其机制尚不清楚。在我们之前的研究中,电解质失衡,特别是恶性腹水中高钠含量,已被确定为损害NK和T细胞活性的主要免疫抑制机制。

在本研究中,我们探讨了高浓度腹水蛋白和免疫球蛋白对抗肿瘤NK效应功能的作用。为此,使用了由健康供体NK细胞和卵巢癌细胞组成的共培养系统。加入抗EGFR抗体Cetuximab以诱导抗体依赖性细胞介导的细胞毒性(ADCC)。在不同患者腹水样本和从腹水中分离的免疫球蛋白存在下,评估了NK活性。

腹水中总体高蛋白浓度损害了NK细胞脱颗粒、与肿瘤细胞的结合以及细胞内钙信号传导。从腹水样本中分离的免疫球蛋白竞争性干扰NK ADCC并抑制与靶细胞的结合。此外,在NK细胞活化过程中,腹水来源的免疫球蛋白阻止了NK细胞上调节性表面标志物CD16和DNAM-1的下调。

展开英文摘要原文

In the present study, we explored the role of high concentrations of ascites proteins and immunoglobulins on antitumoral NK effector functions. To this end, a coculture system consisting of healthy donor NK cells and ovarian cancer cells was used. The anti-EGFR antibody Cetuximab was added to induce antibody-dependent cellular cytotoxicity (ADCC). NK activity was assessed in the presence of different patient ascites samples and immunoglobulins that were isolated from ascites.

Overall high protein concentration in ascites impaired NK cell degranulation, conjugation to tumor cells, and intracellular calcium signaling. Immunoglobulins isolated from ascites samples competitively interfered with NK ADCC and inhibited the conjugation to target cells. Furthermore, downregulation of regulatory surface markers CD16 and DNAM-1 on NK cells was prevented by ascites-derived immunoglobulins during NK cell activation.

Our data show that high protein concentrations in biological fluids are able to suppress antitumoral activity of NK cells independent from the mechanism mediated by imbalanced electrolytes. The competitive interference between immunoglobulins of ascites and specific therapeutic antibodies could diminish the efficacy of antibody-based therapies and should be considered in antibody-based immunotherapies.

论文信息

作者
Hrvat A、Benders S、Kimmig R、Brandau S、Mallmann-Gottschalk N
单位
Experimental and Translational Research, Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany.Germany
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2024
原文标识
PubMed 38646521 · DOI 10.3389/fimmu.2024.1360615